Alto Neuroscience continues march toward the clinic with Series B, hoping to unveil data next year
A year ago, Alto Neuroscience came into the game with a $32 million Series A and plans to launch three Phase IIa trials for several psychiatric disorders, including treatment-resistant depression and PTSD. The company, founded by Stanford neurologist Amit Etkin, was built around predictive technology that his team said could predict PTSD patients’ response to therapy by just looking at brainwaves.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.